Contact

Get in touch

Dymista^®^ twice as effective as fluticasone^1^|(when placebo effect excluded)|

Twice as effective as fluticasone in providing nasal and ocular symptom relief when placebo effect excluded^1^

Faster substantial relief than fluticasone^1^

Days to achieve a 50% reduction of AR symptoms (rTNSS)\nin ≥30% patients

Effective in providing relief in all four major nasal symptoms

LS Mean Change from Baseline in rTNSS

Compared to fluticasone Dymista^®^ significantly improves ocular symptoms


Problem
: Patients with allergic rhinitis suffer from both nasal and ocular symptoms.

Solution: Patients treated with Dymista® experience significantly greater relief from both their nasal and ocular symptoms compared to the current gold standard treatment, fluticasone (FP).1,2,3

In a double-blind, placebo-controlled, 14-day, parallel-group trial, 610 patients (≥12 years old) with moderate-to-severe SAR were randomised to either Dymista, commercially-available azelastine hydrochloride (AZE) or fluticasone propionate (FP) nasal sprays, and placebo (all given as 1 spray/nostril bid [total daily doses: AZE = 548μg; FP=200μg].
†p=0.0013 vs Dymista®; ‡p=0.0004 vs Dymista®.1

  1. Price et al. A new therapy (MP29-02*) effectively targets the entire seasonal allergic rhinitis symptom complex. Abstract accepted by the Symposium on Experimental Rhinology and Immunology of the Nose (SERIN), Leuven (Belgium) 21-23 March 2013.
  2. Carr W, Bernstein J, Lieberman P, et al. J Allergy Clin Immunol 2012;129(5):1282-1289.
  3. Meltzer et al. Clinically Relevant Effect of a New Intranasal Therapy (MP29-02) in Allergic Rhinitis Assessed by Responder Analysis.
    Int Arch Allergy Immunol 2013;161:369–37.


Problem
: Many allergic rhinitis patients do not achieve substantial symptom relief quickly enough.

Solution: Dymista® patients achieve substantial control of their nasal symptoms and do so up to 6 days faster than either fluticasone (FP) or azelastine hydrochloride (AZE).2,3

Randomised, double-blind, placebo-controlled trial in patients (n=610) with moderate-to-severe SAR. Comparing MP29-02 (a novel azelastine/fluticasone formulation) with placebo, fluticasone propionate or azelastine hydrochloride nasal sprays.
†p=0.0223 vs Dymista®; ‡p=0.0284 vs Dymista®1.

  1. Bachert et al. MP29-02 and time to response in the treatment of seasonal allergic rhinitis compared to marketed antihistamine and corticosteroid nasal sprays. Abstract presented at the European Academy of Allergy and Clinical Immunology (EAACI)
    Congress, Istanbul (Turkey) 11-15 June 2011 (abstract No. 285).
  2. Carr W, Bernstein J, Lieberman P, et al. J Allergy Clin Immunol 2012;129(5):1282-1289.
  3. Meltzer et al. Clinically Relevant Effect of a New Intranasal Therapy (MP29-02) in Allergic Rhinitis Assessed by Responder Analysis.
    Int Arch Allergy Immunol 2013;161:369–37

Meltzer et al. Clinically Relevant Effect of a New Intranasal Therapy (MP29-02) in Allergic Rhinitis Assessed by Responder Analysis.
Int Arch Allergy Immunol 2013;161:369–377

“In adults and adolescents with allergic rhinitis, Dymista® Nasal Spray, one spray in each nostril twice daily, significantly improved nasal symptoms (comprising rhinorrhoea, nasal congestion, sneezing and nasal itching) compared with azelastine hydrochloride [AZE] alone and fluticasone propionate [FP] alone”

610 moderate-to-severe SAR patients (≥ 12 years old) were randomized into a double-blind, placebo-controlled, 14-day, parallel group trial.
Change from baseline in the reflective total nasal symptom score (rTNSS) over 14 days was the primary outcome.
Post hoc endpoints included the sum of nasal and ocular symptoms (rT7SS), efficacy by disease severity and by predominant nasal symptom, and a set of responder analyses.

 

 

 

Meltzer et al. Clinically Relevant Effect of a New Intranasal Therapy (MP29-02) in Allergic Rhinitis Assessed by Responder Analysis.
Int Arch Allergy Immunol 013;161:369–37

Dymista®(n=153); FP: Fluticasone propionate (n=151); AZE: azelastine hydrochloride (n=152);
rTOSS: reflective Total Ocular Symptom Score; Data presented as LS mean change from baseline delta placebo with 95% CI